Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth - Nasdaq
Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth Nasdaq
On Jan 25, we issued an updated research report on Inovio Pharmaceuticals, Inc. INO . Inovio's most advanced candidate, VGX-3100 vaccine, has been.
Comments
Post a Comment